Drug · DIN 02304902
REVLIMID
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 31, 2025; first marketed February 19, 2008.
- Drug Identification Number (DIN)
- 02304902
- Company (DIN owner)
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Lenalidomide L04AX04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LENALIDOMIDE | 10 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 9, 2024: NOC 32672New Drug Submission (NDS) · Administrative: Change in Product Ownership
- January 17, 2008: NOC 9303New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “revlimid”. A notice may cover another product or only some lots: read it to see what it covers.
- Revlimid (lenalidomide) - Risk of Liver Problems - For the PublicDecember 27, 2013 · Drugs · New safety information
- Revlimid (lenalidomide) - Risk of Liver Problems - For Health ProfessionalsDecember 27, 2013 · Drugs · New safety information
- Revlimid (lenalidomide) – Association with an Increased Risk of Second Cancers – For the PublicMay 3, 2012 · Drugs · Product safety
- Revlimid (lenalidomide) - Association with an Increased Risk of Second Cancers - For Health ProfessionalsMay 3, 2012 · Drugs
Other DINs named REVLIMID
- DIN 02304899 · Marketed
- DIN 02317699 · Marketed
- DIN 02317710 · Marketed
- DIN 02440601 · Marketed
- DIN 02459418 · Marketed